HLA class II peptide-binding groove (HLA-II PBG)

The HLA class II peptide-binding groove is a critical structural component of Major Histocompatibility Complex (MHC) class II molecules, primarily found on the surface of professional antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages (NIH, 2023). Formed by the alpha-1 and beta-1 domains of the HLA-II heterodimer, the groove features an open-ended topology that allows it to bind and present peptides of varying lengths, typically 13 to 25 amino acids (Frontiers in Immunology, 2022). Its primary biological role is the presentation of exogenous antigens to CD4+ T helper cells, a process essential for the initiation and regulation of the adaptive immune response (NIH, 2018). Polymorphisms within the groove's pockets (P1, P4, P6, P7, and P9) dictate the specificity of the presented peptide repertoire, and specific HLA alleles are strongly linked to the pathogenesis of autoimmune diseases like rheumatoid arthritis, type 1 diabetes, and multiple sclerosis (NIH, 2019). Therapeutically, the groove is targeted by drugs such as glatiramer acetate, which acts as a competitive inhibitor and T-cell receptor antagonist to modulate autoreactive immune responses (Neurology, 2019). Furthermore, the groove is a site of interaction for various small molecules that can cause severe drug hypersensitivity reactions by altering the chemistry of the binding cleft and inducing the presentation of neoantigens (JCI Insight, 2023).

Other names

MHC class II peptide-binding cleftHLA-II antigen-binding grooveHLA-II PBR (peptide-binding region)HLA-II binding site

Competitive inhibition of peptide binding, alteration of the presented peptide repertoire (neoantigen formation), and T-cell receptor (TCR) antagonism.